Solid dosage form

1. A fast disintegrating and dissolving freeze-dried wafer adapted for release and absorption of a biologically active material in an oral cavity wherein the wafer comprises:

a) at least one biologically active material; and

b) amylopectin at 2% to 17% by dry weight of the wafer; and

c) a carbohydrate chosen from a group consisting of: mannitol, dextrose, lactose, galactose, trehalose and cyclodextrin at 5% to 80% by dry weight of the wafer,

wherein the wafer dissolves in the oral cavity, and wherein the biologically active material is chosen from a group consisting of: at least one cyclic guanosine monophosphate (cGMP) phosphodiesterase type 5 (PDE5) inhibitor, an active material that binds to one or more adrenergic receptors, and an N-methyl-D-aspartate receptor antagonist, and when analysed by powder x-ray diffraction (XRD), the wafer exhibits peaks located at 2-theta values of approximately 9.58 degrees, approximately 19.68 degrees, and approximately 20.05 degrees, and

wherein the wafer is free of starch.

2. The freeze-dried wafer solid dosage form of claim 1 wherein the N-methyl-D-aspartate receptor antagonist is chosen from a group consisting of: dextromethorphan, dextrorphan, ketamine, and a pharmaceutically acceptable salt thereof.

3. The freeze-dried wafer of claim 1 wherein the active material that binds to one or more adrenergic receptors is adrenaline (epinephrine), or a pharmaceutically acceptable salt thereof.

4. The freeze-dried wafer solid dosage form of claim 1 wherein the cyclic guanosine monophosphate (cGMP) phosphodiesterase type 5 (PDE5) inhibitor is sildenafil or a pharmaceutically acceptable salt thereof.

5. A method to produce a fast disintegrating and dissolving freeze-dried wafer adapted for release and absorption of a biologically active material in an oral cavity wherein the wafer dissolves in the oral cavity, comprising the steps of:

a) providing a homogenous mixture comprising amylopectin at 2% to 17% by dry weight of the wafer, a carbohydrate chosen from a list consisting of: mannitol, dextrose, lactose, galactose, trehalose and cyclodextrin at 5% to 80% by dry weight of the wafer, and a biologically active material; and

b) freeze drying the mixture to prepare the wafer;

wherein the biologically active material is chosen from a group consisting of: at least one cyclic guanosine monophosphate (cGMP) phosphodiesterase type 5 (PDE5) inhibitor, an active material that binds to one or more adrenergic receptors, and an N-methyl-D-aspartate receptor antagonist; and, when analysed by powder x-ray diffraction (XRD), the wafer exhibits peaks located at 2-theta values of approximately 9.58 degrees, approximately 19.68 degrees, and approximately 20.05 degrees, and wherein the wafer is free of starch.

6. The method of claim 5 wherein the N-methyl-D-aspartate receptor antagonist is chosen from a group consisting of: dextromethorphan, dextrorphan, ketamine, and a pharmaceutically acceptable salt thereof.

7. The method of claim 5 wherein the active material that binds to one or more adrenergic receptors is adrenaline, or a pharmaceutically acceptable salt thereof.

8. The method of claim 5 wherein the cyclic guanosine monophosphate (cGMP) phosphodiesterase type 5 (PDE5) inhibitor is sildenafil or a pharmaceutically acceptable salt thereof.

9. A kit comprising:

a) a fast disintegrating and dissolving freeze-dried wafer adapted for release and absorption of a biologically active material in an oral cavity wherein the wafer dissolves in the oral cavity, wherein the wafer form comprises:

(i) at least one biologically active material, and

(ii) amylopectin at a concentration from 2% to 17% by dry weight of the wafer;

(iii) a carbohydrate chosen from a group consisting of: mannitol, dextrose, lactose, galactose, trehalose and cyclodextrin at a concentration from 5% to 80% by dry weight of the wafer, and

b) instructions for use

wherein the biologically active material is chosen from a group consisting of: at least one cyclic guanosine monophosphate (cGMP) phosphodiesterase type 5 (PDE5) inhibitor, an active material that binds to one or more adrenergic receptors, and an N-methyl-D-aspartate receptor antagonist; and, when analyzed by powder x-ray diffraction (XRD), the freeze dried wafer exhibits peaks located at 2-theta values of approximately 9.58 degrees, approximately 19.68 degrees, and approximately 20.05 degrees, and wherein the wafer is free of starch.

10. The kit of claim 9 wherein the N-methyl-D-aspartate receptor antagonist is chosen from a group consisting of: dextromethorphan, dextrorphan, ketamine, and a pharmaceutically acceptable salt thereof.

11. The kit of claim 9 wherein the active material that binds to one or more adrenergic receptors is adrenaline, or a pharmaceutically acceptable salt thereof.

12. The kit of claim 9 wherein the cyclic guanosine monophosphate (cGMP) phosphodiesterase type 5 (PDE5) inhibitor is sildenafil or a pharmaceutically acceptable salt thereof.

13. A pharmaceutical composition comprising: the freeze-dried wafer of claim 1 .

14. The freeze-dried wafer of claim 1 , wherein the wafer is adapted to not leave a residue of said wafer in the oral cavity that is detectable by a patient.

15. The freeze-dried wafer of claim 1 , wherein the wafer completely dissolves once placed in the oral cavity in a time period selected from a group consisting of: less than 2 minutes; less than 1 minute; less than 50 seconds; less than 40 seconds; less than 30 seconds; less than 20 seconds; less than 15 seconds; less than 10 seconds; less than 7.5 seconds; less than 5 seconds; less than 4 seconds; less than 3 seconds; and less than 2 seconds after administration of the wafer.

16. The freeze-dried wafer of claim 1 , wherein the wafer provides an effective plasma concentration of the biologically active material within a period of no more than two hours, 30 minutes, 20 minutes, or 15 minutes.

17. The freeze-dried wafer of claim 16 , wherein the period is within 10 minutes.